Importantly, these determinants are interdependent and may amplify or attenuate one another within a complex host-microbe-drug network (128)
In schizophrenia, GLP-1 receptor agonists improve metabolic health but not core psychotic symptoms
Koperska, A., Wesoek, A., Moszak, M., & Szuliska, M
The result is countless policy and price changes and a lot of confusion
Regular evaluations, especially after multiple sessions, ensure that patients are getting the results they expect
Interfering with their use of it (through drugs called glutaminase inhibitors) could be a potential treatment approach